We are conducting two prospective multicenter studies: CBCSG026 trial (NCT03541278) was designed to verify the repeatability of this high IMSLN visualization rate in patients with both ALN negative and positive breast cancer (a minimum of 350 patients for enrollment); the CBCSG027 trial (NCT03024463) of IM-SLNB followed by the 1st to 3rd intercostal IMLN dissection was designed to verify the IM-SLNB accuracy in ALN-positive patients (at least 40 patients with positive IMLN required). This evidence concerns the gene ARLN and breast carcinoma.